Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads eye scans to spot thyroid disease activity and severity

NCT ID NCT07716397

Diagnosis Sponsor: Shanghai Changzheng Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study tests whether an artificial intelligence (AI) model can accurately diagnose thyroid eye disease, assess its activity and severity, and predict its outcome using specialized MRI scans of the eye socket. Researchers will enroll 1200 people, including patients with thyroid eye disease, people with other eye conditions, and healthy volunteers. Participants undergo a detailed MRI and an eye ultrasound, and the AI analyzes the images to see if it matches expert clinical assessments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI scan and ocular ultrasound with AI analysis
What this could lead to
If successful, this AI model could provide a fast, objective tool for diagnosing and monitoring thyroid eye disease, helping doctors choose the right treatment earlier.
What could go wrong
This is an observational study, not a treatment trial. The AI model may not perform as well in real-world settings as expected, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Before initiating the corresponding procedures for the study, all subjects must personally sign the informed consent form approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB) and indicate the date.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * TAO patient group * Age between 18 and 75 years old, regardless of gender. * Patients with thyroid eye disease who meet the disease staging and grading criteria specified in diagnostic guidelines such as those of Bartley, CAS, and EUGOGO. * The patient has planned or received thyroid-related treatment, and the condition is relatively stable. * Voluntarily participate in this study and sign the informed consent form. Control group: ① Healthy volunteers matched with the TAO group in terms of age and gender. ② Voluntarily participate in this study and sign the informed consent form. Exclusion Criteria: * TAO patient group: * Pregnant or lactating women. * Patients with other orbital lesions. ③ Having contraindications for MRI examination (such as non - compatible metal implants in the body, claustrophobia, etc.). ④ The patient has previously received orbital radiotherapy or orbital surgery (except for patients who need to collect tissue specimens). ⑤ Comorbid with other severe systemic diseases (such as uncontrolled heart failure, liver and kidney failure) or mental illnesses, and unable to cooperate to complete the study. ⑥ Participated in other clinical trials that may interfere with the results of this study within 3 months. Control group: Same as the exclusion criteria 1 - 6 for the TAO patient group

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves disease Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graves disease Graves ophthalmopathy Thyroid associated ophthalmopathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Shanghai Changzheng Hospital

    RECRUITING

    Shanghai, Huangpu District, 200003, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.